Literature DB >> 2474616

The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants.

A S Cross1, H Sidberry, J C Sadoff.   

Abstract

The class-specific antibody response was measured in sequential serum samples from 17 patients after natural bacteremic infection with gram-negative bacilli. There was a five- to sevenfold mean increase over preexisting antibody in levels of IgG (range, less than 1-to 88-fold), IgA (1- to 83-fold), and IgM (less than 1- to 58-fold) antibody to homologous lipopolysaccharide (LPS) in 16 of these patients. In contrast, there was only a two- to threefold mean increase (range, less than 1- to 78-fold) in about half of the patients who had a detectable antibody response to J5 core determinants and in the third who responded to Re core determinants (range, 1- to 20-fold). All but one of the infective strains of bacteria were smooth on analysis with SDS-PAGE and with rough-specific phages. Humans infected with bacteria that had a rough LPS phenotype, however, did elicit antibody similar to that induced in rabbits after immunization with J5 vaccine. Thus, the human antibody response to natural infection with gram-negative bacilli appears to be directed primarily at homologous, strain-specific epitopes, and the response to the epitopes of LPS core antigens is not against widely shared determinants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474616     DOI: 10.1093/infdis/160.2.225

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

2.  IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease?

Authors:  Alexandr Parlesak; Christian Schäfer; Christiane Bode
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

3.  The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome.

Authors:  A Myc; J Buck; J Gonin; B Reynolds; U Hammerling; D Emanuel
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  The costimulatory immunogen LPS induces the B-Cell clones that infiltrate transplanted human kidneys.

Authors:  Rajesh K Grover; Julong Cheng; Yingjie Peng; Teresa M Jones; Diana I Ruiz; Richard J Ulevitch; John I Glass; Edward A Dennis; Daniel R Salomon; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-06       Impact factor: 11.205

5.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.

Authors:  G Behre; I Schedel; B Nentwig; B Wörmann; M Essink; W Hiddemann
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Emerging Pathogenic and Prognostic Significance of Paired Box 3 (PAX3) Protein in Adult Gliomas.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Transl Oncol       Date:  2019-07-25       Impact factor: 4.243

Review 9.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.